BRAF driver mutations in NSCLC are rare at 2 % [1, 2], but tumours with BRAFV600E mutations have histological features suggestive of aggressive biology [3]. When treated with platinum-based chemotherapy, these patients showed less favourable outcomes [3, 4]. Read more ...
10.10.2017 | Onkologie | Online-Artikel